The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1541
February 26, 2018
View Complete Issue         Table of Contents 2019 
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
February 26, 2018 (Issue: 1541)
The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is the first sublingual allergen extract...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
Article code: 1541c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.